FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386947885> ?p ?o ?g. }

• W4386947885 endingPage "101623" @default.
• W4386947885 startingPage "101623" @default.
• W4386947885 abstract "Eftilagimod alpha (efti) is a major histocompatibility complex class II agonist activating antigen-presenting cells which leads to greater systemic type 1 T helper response and more cytotoxic CD8+ T-cell activation. This phase I trial evaluated the administration of efti, a soluble lymphocyte activation gene-3 (LAG-3) protein, combined with the anti-programmed death-ligand 1 (PD-L1) antibody avelumab in advanced solid tumors.Patients with heavily pretreated metastatic solid tumors received intravenous avelumab (800 mg) combined with subcutaneously administered efti (6 or 30 mg) for up to 12 cycles, followed by avelumab monotherapy. The primary endpoint was the assessment of the recommended phase II dose (RP2D) of efti in combination with avelumab.Twelve patients with different tumor entities were enrolled (six patients in each cohort). During treatment, no dose-limiting toxicities occurred, and the severity of most adverse events was grade 1 or 2. In total, nine serious adverse events were documented, resulting in a fatal outcome in two cases, but none of them were assessed to be treatment related. Five patients (42%) achieved partial response. The median progression-free survival was 1.96 months and the median overall survival was not reached, with a 12-month survival rate of 75%.Subcutaneously administered efti plus avelumab was well tolerated, and efti of 30 mg was determined to be RP2D. The activity is promising and warrants further investigation in future phase II trials." @default.
• W4386947885 created "2023-09-23" @default.
• W4386947885 creator A5001432303 @default.
• W4386947885 creator A5013226213 @default.
• W4386947885 creator A5019375817 @default.
• W4386947885 creator A5023227183 @default.
• W4386947885 creator A5032057646 @default.
• W4386947885 creator A5037604059 @default.
• W4386947885 creator A5043901757 @default.
• W4386947885 creator A5051396704 @default.
• W4386947885 creator A5053206032 @default.
• W4386947885 creator A5054910113 @default.
• W4386947885 creator A5055092398 @default.
• W4386947885 creator A5062748174 @default.
• W4386947885 creator A5074153585 @default.
• W4386947885 creator A5076298207 @default.
• W4386947885 creator A5084519979 @default.
• W4386947885 date "2023-10-01" @default.
• W4386947885 modified "2023-10-03" @default.
• W4386947885 title "A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology" @default.
• W4386947885 cites W1519288670 @default.
• W4386947885 cites W1524533358 @default.
• W4386947885 cites W1594539813 @default.
• W4386947885 cites W1606078320 @default.
• W4386947885 cites W1992249154 @default.
• W4386947885 cites W2030995912 @default.
• W4386947885 cites W2047958526 @default.
• W4386947885 cites W2049553585 @default.
• W4386947885 cites W2079967205 @default.
• W4386947885 cites W2100086637 @default.
• W4386947885 cites W2101477183 @default.
• W4386947885 cites W2127402662 @default.
• W4386947885 cites W2132976465 @default.
• W4386947885 cites W2198093519 @default.
• W4386947885 cites W2291298003 @default.
• W4386947885 cites W2488042065 @default.
• W4386947885 cites W2529484692 @default.
• W4386947885 cites W2586157991 @default.
• W4386947885 cites W2587048937 @default.
• W4386947885 cites W2599354912 @default.
• W4386947885 cites W2767891987 @default.
• W4386947885 cites W2808822836 @default.
• W4386947885 cites W2883552436 @default.
• W4386947885 cites W2903493423 @default.
• W4386947885 cites W2913788177 @default.
• W4386947885 cites W2919913683 @default.
• W4386947885 cites W2925446385 @default.
• W4386947885 cites W2938155964 @default.
• W4386947885 cites W2946126594 @default.
• W4386947885 cites W2953997311 @default.
• W4386947885 cites W2982043866 @default.
• W4386947885 cites W3028523516 @default.
• W4386947885 cites W3037531509 @default.
• W4386947885 cites W3137268919 @default.
• W4386947885 cites W3138260539 @default.
• W4386947885 cites W3155244800 @default.
• W4386947885 cites W3171467378 @default.
• W4386947885 cites W3174446256 @default.
• W4386947885 cites W3197978811 @default.
• W4386947885 cites W3212705462 @default.
• W4386947885 cites W4229029508 @default.
• W4386947885 cites W4281665196 @default.
• W4386947885 cites W4282839227 @default.
• W4386947885 doi "https://doi.org/10.1016/j.esmoop.2023.101623" @default.
• W4386947885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37742484" @default.
• W4386947885 hasPublicationYear "2023" @default.
• W4386947885 type Work @default.
• W4386947885 citedByCount "0" @default.
• W4386947885 crossrefType "journal-article" @default.
• W4386947885 hasAuthorship W4386947885A5001432303 @default.
• W4386947885 hasAuthorship W4386947885A5013226213 @default.
• W4386947885 hasAuthorship W4386947885A5019375817 @default.
• W4386947885 hasAuthorship W4386947885A5023227183 @default.
• W4386947885 hasAuthorship W4386947885A5032057646 @default.
• W4386947885 hasAuthorship W4386947885A5037604059 @default.
• W4386947885 hasAuthorship W4386947885A5043901757 @default.
• W4386947885 hasAuthorship W4386947885A5051396704 @default.
• W4386947885 hasAuthorship W4386947885A5053206032 @default.
• W4386947885 hasAuthorship W4386947885A5054910113 @default.
• W4386947885 hasAuthorship W4386947885A5055092398 @default.
• W4386947885 hasAuthorship W4386947885A5062748174 @default.
• W4386947885 hasAuthorship W4386947885A5074153585 @default.
• W4386947885 hasAuthorship W4386947885A5076298207 @default.
• W4386947885 hasAuthorship W4386947885A5084519979 @default.
• W4386947885 hasConcept C121608353 @default.
• W4386947885 hasConcept C126322002 @default.
• W4386947885 hasConcept C143998085 @default.
• W4386947885 hasConcept C147483822 @default.
• W4386947885 hasConcept C159654299 @default.
• W4386947885 hasConcept C167672396 @default.
• W4386947885 hasConcept C197934379 @default.
• W4386947885 hasConcept C203014093 @default.
• W4386947885 hasConcept C2777381376 @default.
• W4386947885 hasConcept C2777701055 @default.
• W4386947885 hasConcept C2780030458 @default.
• W4386947885 hasConcept C71924100 @default.
• W4386947885 hasConcept C90924648 @default.
• W4386947885 hasConceptScore W4386947885C121608353 @default.

• next